Literature DB >> 33735470

Phosphorus levels in children treated with intravenous ferric carboxymaltose.

Susan E Kirk1, Michael E Scheurer1, Melanie Brooke Bernhardt1, Donald H Mahoney1, Jacquelyn M Powers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33735470      PMCID： PMC8113159          DOI： 10.1002/ajh.26165

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


× No keyword cloud information.
  5 in total

Review 1.  Advances in Pediatric Intravenous Iron Therapy.

Authors:  Elpis Mantadakis
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

2.  Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.

Authors:  Jacquelyn M Powers; Mark Shamoun; Timothy L McCavit; Leah Adix; George R Buchanan
Journal:  J Pediatr       Date:  2016-10-21       Impact factor: 4.406

3.  Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.

Authors:  Myles Wolf; Janet Rubin; Maureen Achebe; Michael J Econs; Munro Peacock; Erik A Imel; Lars L Thomsen; Thomas O Carpenter; Thomas Weber; Vincent Brandenburg; Heinz Zoller
Journal:  JAMA       Date:  2020-02-04       Impact factor: 56.272

4.  Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.

Authors:  Thomas J Weber; L Darryl Quarles
Journal:  Curr Mol Biol Rep       Date:  2019-02-09

5.  Hypophosphatemia in children treated with ferric carboxymaltose.

Authors:  Anna Posod; Benedikt Schaefer; Thomas Mueller; Heinz Zoller; Ursula Kiechl-Kohlendorfer
Journal:  Acta Paediatr       Date:  2020-01-28       Impact factor: 2.299
  5 in total
  3 in total

1.  Safety of Ferric Carboxymaltose in Children: Report of a Case Series from Greece and Review of the Literature.

Authors:  Paraskevi Panagopoulou; Sonia Alexiadou; Maria Ntoumpara; Anna Papazoglou; Alexandros Makis; Athanasios Tragiannidis; Maria Fotoulaki; Elpis Mantadakis
Journal:  Paediatr Drugs       Date:  2022-01-27       Impact factor: 3.022

2.  High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.

Authors:  Johannes M M Boots; Rogier A M Quax
Journal:  Drug Saf       Date:  2022-09-06       Impact factor: 5.228

Review 3.  Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.

Authors:  Aysegül Aksan; Fred Zepp; Sangeetha Anand; Jürgen Stein
Journal:  Eur J Pediatr       Date:  2022-09-02       Impact factor: 3.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.